• Fri news: Pfizer’s $1B Chinese commitment. RFK Jr. and pharma. Eisai dials back Leqembi forecast. US diabetes burden increase. JNJ gets Varipulse approval. See more on our front page

What happened to allergy positions?

I’m also in the the interview process. Any thoughts on how well this product and division are expected to do? I have a couple other options I’m looking into and just want to make the right call. Sounds like virtual training in December for new hires.
Go with the other offers Especially since you have not received an offer here. A bird in the hand is worth 2 in the bush.
 












































I’m also in the the interview process. Any thoughts on how well this product and division are expected to do? I have a couple other options I’m looking into and just want to make the right call. Sounds like virtual training in December for new hires.
High risk for failure comparable with Deucravacitinib in psoriasis, less effective more side effects than Omalizumab but same price range, poor US americans will use cheapest OTC antihistamines plus high dose Vitamin C for csU instead
 












True enough. Obviously the positions have been delayed and training wouldn’t take place now until December or so. I was more curious how good of a job this would be once Reme was approved. Thanks.
We really don’t know. This drug has to succeed. Novartis is putting a lot of money behind it. The first year will probably be great. Lots of hype and enthusiasm. Beyond that it’s a toss up. If performance is good then everyone is happy. If it’s not good, who knows what the environment will be
 




We really don’t know. This drug has to succeed. Novartis is putting a lot of money behind it. The first year will probably be great. Lots of hype and enthusiasm. Beyond that it’s a toss up. If performance is good then everyone is happy. If it’s not good, who knows what the environment will be
Thank you for the honest feedback. I know there are always risks with new divisions and new product launches. Nothing is ever guaranteed but if they go well the potential to make a lot of money is there. Thanks again!
 




We really don’t know. This drug has to succeed. Novartis is putting a lot of money behind it. The first year will probably be great. Lots of hype and enthusiasm. Beyond that it’s a toss up. If performance is good then everyone is happy. If it’s not good, who knows what the environment will be
"The drug has to succeed".
Let me think, where have I heard that before.
That's right! They spend $9B dollars on a medication that "had to succeed" and engaged in such embarrassing fuckery they're going to have to lay off half the C.V. team.
If you are pinning your hopes on Novartis launching a medication "that has to succeed", and doing it correctly, you are either new or you don't pay attention.
Either way, good luck.
 




"The drug has to succeed".
Let me think, where have I heard that before.
That's right! They spend $9B dollars on a medication that "had to succeed" and engaged in such embarrassing fuckery they're going to have to lay off half the C.V. team.
If you are pinning your hopes on Novartis launching a medication "that has to succeed", and doing it correctly, you are either new or you don't pay attention.
Either way, good luck.
You just said everything I wanted to say, but I am not part of CV and can’t speak from experience. I think because of the leqvio disaster that they created there will be ten times the pressure on the allergy team, just not right away. Novartis can not have another failure
 








I’m also in the the interview process. Any thoughts on how well this product and division are expected to do? I have a couple other options I’m looking into and just want to make the right call. Sounds like virtual training in December for new hires.
Run far and run fast away from Novartis. Almost every single employee is a know it all and tries to tell you how to do your job. Novartis is a terrible company to work for. Just read the CV threads.